Company Profile

Syndax Pharmaceuticals Stock Price, News & Catalysts

Ticker:
SNDX
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

9.13 USD (+6.66%)

Close

Last updated: November 19, 2026

1.63B USD

Market cap

Why the stock is moving

As of Nov 19, 2026, SNDX closed up 6.66% at $9.13. No new same-company headline was identified in the current news window.

Company overview

Commercial Oncology Portfolio

Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo.

Revuforj

Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible genetic drivers. Ongoing studies evaluate frontline combinations, post-transplant maintenance and additional molecular subgroups, including NPM1-mutant, KMT2A-rearranged and NUP98-rearranged disease.

Niktimvo

Niktimvo, or axatilimab, targets CSF-1 receptor biology and is commercialized for chronic graft-versus-host disease. Syndax is testing the molecule in newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis to expand beyond its initial indication.

Frontline Registrational Strategy

Syndax is advancing pivotal trials intended to establish revumenib in frontline acute myeloid leukemia. It also plans the RAVEN study as part of the asset’s broader development program.

Future catalysts

  • New and updated revumenib clinical and real-world data in the fourth quarter of 2026.
  • Initiation of the RAVEN frontline trial and a revumenib myelofibrosis proof-of-principle trial in the fourth quarter of 2026.
  • Initiation of the MenTain post-transplant-maintenance trial and Phase 2 axatilimab-plus-ruxolitinib data in the first quarter of 2027.
  • IND submission for SNDX-4321 by year-end 2026 and Phase 1 initiation in 2027.
  • Initial revumenib myelofibrosis data in the second half of 2027, followed by an SNDX-62122 IND and Phase 1 start in the fourth quarter of 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Syndax Pharmaceuticals (SNDX)?

Syndax Pharmaceuticals (SNDX) most recently closed at 9.13 USD, a +6.66% move versus the previous session.

What is the market cap of Syndax Pharmaceuticals (SNDX)?

Syndax Pharmaceuticals currently has a market capitalization of 1.63B USD on BioPharmSignal.

What does Syndax Pharmaceuticals do?

Commercial Oncology Portfolio Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo. Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible genetic drivers....

On which exchange is SNDX stock listed?

Syndax Pharmaceuticals (SNDX) is associated with NASDAQ, United States, Biopharma.

What is CSF-1?

Niktimvo Niktimvo, or axatilimab, targets CSF-1 receptor biology and is commercialized for chronic graft-versus-host disease.

Which conditions is Syndax Pharmaceuticals targeting with CSF-1?

Syndax Pharmaceuticals is associated with oncology, genetic disease based on its company overview and current catalyst commentary.

How does Syndax Pharmaceuticals describe recent progress with CSF-1?

New and updated revumenib clinical and real-world data in the fourth quarter of 2026. Initiation of the RAVEN frontline trial and a revumenib myelofibrosis proof-of-principle trial in the fourth quarter of 2026. Initiation of the MenTain post-transplant-maintenance trial and Phase 2 axatilimab-plus-ruxolitinib data in the first quarter of 2027. IND...

What is SNDX-4321?

IND submission for SNDX-4321 by year-end 2026 and Phase 1 initiation in 2027.